Ambrx, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on the development of innovative protein therapeutics. Founded in 2003, Ambrx has made significant strides in the field of drug development, particularly in the areas of oncology and autoimmune diseases. The company is renowned for its proprietary technology that enables the incorporation of non-canonical amino acids into proteins, enhancing their therapeutic potential. With a strong presence in both the US and international markets, Ambrx has established itself as a leader in the biopharmaceutical industry. Its core offerings include a range of engineered protein therapeutics that stand out for their improved efficacy and safety profiles. Notable achievements include strategic partnerships and collaborations that have bolstered its market position, making Ambrx a key player in advancing next-generation therapies.
How does Ambrx, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Ambrx, Inc.'s score of 78 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ambrx, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation. Ambrx is aligned with several climate initiatives through Johnson & Johnson, which include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all at a cascade level of 1. However, specific reduction targets or achievements for Ambrx itself have not been disclosed. As part of its corporate family, Ambrx is expected to adhere to the sustainability and climate strategies set forth by Johnson & Johnson, which are designed to reduce overall carbon emissions and enhance environmental responsibility. The absence of direct emissions data suggests that Ambrx is still in the process of establishing its own specific climate commitments, while leveraging the frameworks and targets of its parent company.
Access structured emissions data, company-specific emission factors, and source documents
1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ambrx, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.